sequential emergence of resistance to multiple antimicrobial agents in kpc-producing-klebsiella pneumoniae
نویسندگان
چکیده
introduction klebsiella pneumoniae is one of the most important gram-negative bacteria causing hospital-acquired infections. case presentation in this report is presented a patient with an abdominal infection caused by carbapenemase producing-klebsiella pneumonia (k. pneumonia). in spite of administrating the combination therapy, successive resistance to last-resort antimicrobial agents (colistin and tigecycline) was observed. the use of combination therapy, in four successive isolates recovered from this patient, was analyzed by killing curves. the genetic relatedness among the isolates was assessed. conclusions all four isolates were klebsiella pneumoniae carbapenemase (kpc) positive and showed resistance to all β-lactams including carbapenems and to other antimicrobial agents like aminoglycosides, fluoroquinolones, minocycline and trimetoprim-sulfametoxazol (tms). isolates 1 and 2 showed susceptibility to colistin, whereas isolate 3 was colistin-resistant and isolate 4 became tigecycline-resistant as well. synergy was only observed with colistin plus rifampicin and with the triple combination of colistin, rifampicin and fosfomycin. the four isolates were indistinguishable genotypically. we described the sequential emergence of resistance to colistin and tigecycline in kpc-producing-k. pneumonia (kpc-kp) isolates that occurred under treatment with these antimicrobial agents despite the use of combination therapy.
منابع مشابه
Diversity, virulence, and antimicrobial resistance of the KPC-producing Klebsiella pneumoniae ST307 clone
The global spread of Klebsiella pneumoniae producing Klebsiella pneumoniae carbapenemase (KPC) has been mainly associated with the dissemination of high-risk clones. In the last decade, hospital outbreaks involving KPC-producing K. pneumoniae have been predominantly attributed to isolates belonging to clonal group (CG) 258. However, results of recent epidemiological analysis indicate that KPC-p...
متن کاملKPC-producing Klebsiella pneumoniae, finally targeting Turkey
We report here the first identification of the worldwide spread of Klebsiella pneumoniae carbapenemase-2-producing and carbapenem-resistant K. pneumoniae clone ST258 in Turkey, a country where the distantly-related carbapenemase OXA-48 is known to be endemic. Worryingly, this isolate was also resistant to colistin, now considered to be the last-resort antibiotic for carbapenem-resistant isolates.
متن کاملKlebsiella pneumoniae with multiple antimicrobial resistance.
A Klebsiella pneumoniae strain was isolated from the urine of a patient at one of the centers participating in the 2001 edition of the MYSTIC program in Brazil. The initial phenotypic findings of the isolated K. pneumoniae presented an unusual MIC of 8 microg/mL to meropenem, 2 microg/mL to imipenem, elevated MICs to broad spectrum cephalosporins (ceftazidime/cefotaxime/cefepime MIC > 256 micro...
متن کاملManagement of infections due to KPC-producing Klebsiella pneumoniae
The emergence of the Klebsiella pneumoniae carbapenemases in K. pneumoniae and other Gram-negative bacteria, usually on a background of multidrug resistance, has led to difficult therapeutic choices. Among available antibiotics, tigecycline and the polymyxins are the most frequently active against these organisms in vitro. Optimal therapy of infections due to these bacteria may involve maximiza...
متن کاملEmergence of KPC-producing Klebsiella pneumoniae ST512 isolated from cerebrospinal fluid of a child in Algeria
We report class A carbapenemase (KPC)-3-producing Klebsiella pneumoniae meningitis in a 6-month-old child in Algeria. Multilocus sequence typing showed that the sequence type obtained corresponded to ST512, an allelic single-locus variant of the pandemic ST258 widely distributed in KPC producers from Europe. To our knowledge, this is the first report of KPC-3-producing K. pneumoniae ST512 in a ...
متن کاملMeropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Vaborbactam (formerly RPX7009) is a new β-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against Klebsiella pneumoniaecarbapenemases (KPC). It has been developed in combination with meropenem. The objective of these studies was to identify the concentrations of both agents associated with the selection or prevention of single-step mutations lead...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of infectionجلد ۱، شماره ۲، صفحات ۰-۰
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023